Field of Interest. Executive recognizes and acknowledges the competitive and proprietary nature of the Corporation’s business operations. Executive acknowledges and agrees that a business will be deemed competitive with the Corporation if it provides products or services related to the current or proposed products or services, or information now or hereafter provided or offered by the Corporation or under development by the Corporation that are in the Corporation’s “Field of Interest.” For purpose of clarity, the Corporation’s Field of Interest is the discovery, development, commercialization and marketing of therapeutics (i) based on kinase inhibitors discovered through Mimetica and OPAL, (ii) pre-tubulin polymerization inhibitors, small molecules against OraA1, or (iv) P-glycoprotein inhibitors based on HM30181A for enhanced oral absorption.
Appears in 2 contracts
Sources: Employment Agreement (Athenex, Inc.), Employment Agreement (Athenex, Inc.)